|
|
|
|
|
Dr. MD. KAMRUL HASAN
|
|
|
|
|
|
|
|
|
Address 1
|
:
|
|
|
Address 2
|
:
|
|
|
Title
|
:
|
Dr.
|
|
First Name
|
:
|
MD. KAMRUL
|
|
Last Name
|
:
|
HASAN
|
|
University/Institution
|
:
|
University of California, San Diego
|
|
Email ID
|
:
|
k0hasan@ucsd.edu
|
|
City
|
:
|
San Diego
|
|
Country
|
:
|
United States
|
|
State
|
:
|
California
|
|
Zipcode
|
:
|
92093
|
|
|
|
|
|
|
Department
|
:
|
Department of Medicine
|
|
Company Name
|
:
|
|
|
Area of Research
|
|
Cancer Biology, Drug Development
|
|
Area of Expertise
|
|
Cancer, Molecular Biology, Cell Biology, Gene expression, Transcriptional regulation, Molecular Signaling, Cell growth, Migration, Invasion, Metastises.
|
|
Brief Description of Research Interest :
|
|
Research Interest:
Oncology (Cancer), Cell Biology, Molecular Biology, Cell growth, Migration, Invasion, Metastasis, Gene expression, Transcriptional regulation, Molecular Signaling, Drug Development.
The overarching aim of my research is to unravel the molecular mechanisms of oncogenesis, aggressive behavior, as well as developing novel therapeutic strategies for the treatment of cancer, with a particular emphasis on Chronic Lymphocytic Leukemia (CLL), Neuroblastoma and Breast Cancer. My major interest is to unveil the receptors (ROR1, ALK, NLRR1,2,3) mediated pathways, AKT-mediated pathways, role of Rho family GTPases and remodulation of the actin cytoskeleton in cancer cell survival, migration and metastasis. Cancer treatment strategies are changing from general chemotherapeutic agents to drugs that target specific proteins and signaling pathways. I am also interested to develop targeted therapies that are more effective and less toxic for patients with cancer. So far, I have published 5 manuscripts in reputed peer review journals including Scientific Reports (Nature) and Cancer Medicine. I also have published 31 abstracts in different international conferences.
|
|
Representative Publications :
|
1. Md. Kamrul Hasan, Heggo Asmaa, Atsushi Takatori, Satoshi Kishida, Miki Ohira, YusukeSuenaga Md. Shamim Hossain, Jesmin Akter, Atsushi Ogura, Yohko Nakamura, KenjiKadomatsu, and Akira Nakagawara . ALK is a MYCN target gene and regulates cell migrationand invasion in neuroblastoma. Scientific Reports (Nature) 3, 3450 (2013).
2. Yohko Nakamura, Akiko Suganami, Mayu Fukuda, Md. Kamrul Hasan, Tomoki Yokochi,Atsushi Takatori, Shunpei Satoh, Tyuji Hoshino, Yutaka Tamura and Akira Nakagawara.Identification of novel candidate compounds targeting TrkB to induce apoptosis inneuroblastoma. Cancer Medicine. 3(1), 25-35 (2014).
3. Md. Kamrul Hasan, Md. Ajijur Rahman, Sharif Mohammad Shahin, and Md. Anwar UlIslam. In-Vitro and In-Vivo Evaluation of a Rosiglitazone Maleate-loaded HPMC-PVA BlendPatch. Bangladesh Pharmaceutical Journal. 13 (2), 60-63 (2010).
4. Sharif Mohammad Shahin, Md. Kamrul Hasan. Kanamycin potential of papaya fruit stemexudate in E. Coli. International Journal of Pharma Sciences and Scientific Research. 1 (1), 13-15(2015).
5. Md. Kamrul Hasan, Md. Ajijur Rahman, Sharif Mohammad Shahin, and Md. Anwar UlIslam. Comparative Evaluation of Pioglitazone HCl and Gliclazide -loaded HPMC-PVA BlendPatches. (International Journal of Pharma Sciences and Research. 7 (5), 1904-08 (2016).
6. Afzal Sheikh, Md. Shamim Hossain, Atsushi Takatori, Md. Kamrul Hasan, YohkoNakamura, Akira Nakagawara. NLRR2 is transcriptionally regulated through JNK/c-Jun andenhances cell survival in neuroblastoma. (Cancer Science, Accepted, 2016).
|
|
Resume
|
:
|
Download
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|